Zavzpret
Gepant, CGRP receptor antagonist
Zavzpret
Zavzpret (zavegepant)
Zavzpret (zavegepant) is the first intranasally administered CGRP receptor antagonist (gepant), FDA-approved in March 2023 for the acute treatment of migraine in adults. Its nasal route delivers faster onset than oral gepants, useful when nausea precludes pills.
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Pharmacy
Starting dose
10 mg (one spray) intranasally in one nostril
Preparations
10 mg/spray nasal solution
US FDA Max
10 mg per 24 h
Common uses
Classification(s)
Classes
Gepant, CGRP receptor antagonist
Pharmacology
Routes
Intranasal
Onset
Pain relief reported within 15 min in trials
Duration
~48 h sustained pain freedom in responders
Half-life
~6.6 h
Bioavailability
~5% intranasal
Pregnancy
Limited data; avoid
Legal status
Rx
Purported mechanism
Small-molecule CGRP receptor antagonist; intranasal formulation